The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Sponsor
Attikon Hospital
Study ID
NCT06611904
Status
Active Not Recruiting

Conditions

  • Arterial Stiffness
  • Glycocalyx
  • Urine Albumin (UAlb)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dulaglutide — DRUG
    Combined treatment with dulaglutide and dapagliflozin
  • DPP-4 Inhibitors — DRUG
    DPP-4i treatment as an add-on to metformin

Study Details

Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.

Key Dates

Start date
Feb 1, 2018
Status verified
Sep 2024
Primary completion
Feb 5, 2022
Completion
Dec 15, 2024

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Active Comparator: Patients receiving dulaglutide and dapagliflozin
    Patients with T2DM and albuminuria receiving dulaglutide and dapagliflozin
  • Active Comparator: Patients receiving DPP-4i
    Patients with T2DM and albuminuria receiving DPP-4i

Primary Outcome Measure

UACR [ Time Frame: 4 and 12 months ]

Related Studies